Takeda Drops One Hunter Syndrome Therapeutic, Puts Faith in Another

Takeda Drops One Hunter Syndrome Therapeutic, Puts Faith in Another

Source: 
BioSpace
snippet: 

In its financial results for 2021, released Wednesday, Takeda announced that it has decided to discontinue the development of TAK-609, a therapeutic for Hunter Syndrome.